Krystal Biotech (KRYS) Revenue (2023 - 2026)

Krystal Biotech has disclosed Revenue across 4 years of filings, most recently posting $116.4 million for Q1 2026.

• Revenue for Q1 2026 came in at $116.4 million, up 31.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $417.3 million (up 25.14% YoY), and the FY2025 annual result was $389.1 million, up 33.93% from the prior year.
• Revenue came in at $116.4 million for Q1 2026 at Krystal Biotech, up from $107.1 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $116.4 million in Q1 2026 to a low of $8.6 million in Q3 2023.
• The 4-year median for Revenue is $88.2 million (2025), against an average of $77.0 million.
• Across the five-year window, Revenue soared 879.91% in 2024 and rose 16.65% in 2025, its largest moves.
• Krystal Biotech's Revenue stood at $42.1 million in 2023, then soared by 116.2% to $91.1 million in 2024, then gained by 17.54% to $107.1 million in 2025, then increased by 8.64% to $116.4 million in 2026.
• The last three Revenue figures came in at $116.4 million (Q1 2026), $107.1 million (Q4 2025), and $97.8 million (Q3 2025), per Business Quant data.